CLINICAL ROLE -
Lung Cancer: Copayments and Behavior Following Erlotinib Formulary Tier Change
Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.
Read More